| Today’s Big NewsMar 4, 2025 |
|
Tuesday, March 11, 2025 | 11am ET / 8am PT In the world of clinical trials, where precision and compliance are critical, the role of technology is more important than ever. Join us to learn how to harness the latest innovations for driving efficiencies and more streamlined experiences for patients. Register now to take a deep dive into the most pressing challenges in clinical trials today! 
|
|
| By Fraiser Kansteiner Pfizer’s local manufacturing setup is already well positioned in the U.S., and the New York-based drugmaker could bring additional resources into the country if pharma import tariffs proposed by President Donald Trump take effect, the company's CEO, Albert Bourla, Ph.D., said Monday. |
|
|
|
By James Waldron Atara Biotherapeutics is halving its head count as it navigates the fallout from the FDA’s move to halt on all of the allogeneic T-cell company’s attempts to launch fresh clinical trials. |
By Conor Hale Illumina has been barred from exporting its DNA sequencers to China, which closed its doors to the company in response to the Trump administration expanding its tariffs on the country. |
By Kevin Dunleavy Gilead set aside approximately $200 million for a potential resolution of an eight-year case surrounding its promotional speaker program for HIV drugs. |
By Angus Liu Merck & Co. is leveraging March 4’s International HPV Awareness Day for a marketing campaign in China, lighting up landmark buildings in four megacities in the hopes of reigniting demand amid floundering sales of its vaccine Gardasil. |
By Darren Incorvaia Deal-happy Novartis is further bolstering its preclinical pipeline and continuing its hunt for a Xolair successor, nailing down a licensing pact with Japanese biotech Kyorin potentially worth hundreds of millions of dollars. |
By Nick Paul Taylor Takeda made it rain zebras at a Boston Celtics game Friday. The stunt saw 100 toy zebras parachute from the arena’s rafters to represent the complex journeys of individuals with rare diseases. |
By Zoey Becker The companies claim that Moderna stepped on their lipid nanoparticle technology with its COVID vaccine Spikevax and RSV vaccine mRESVIA. |
By Darren Incorvaia Private equity giant Blackstone is going big on Japan, acquiring a majority stake in the country’s leading contract research organization. |
By Angus Liu AstraZeneca and Daiichi Sankyo's Enhertu has become the first HER2-directed drug to mount a patient survival benefit in a randomized clinical trial in second-line metastatic stomach cancer, the partners said on Monday. |
By Gabrielle Masson Acelyrin consulted with independent advisors and came to the conclusion that the unsolicited interest from Tang Capital Partners-owned Concentra was “not reasonably expected to result in a superior proposal to the planned merger with Alumis." |
By Fraiser Kansteiner Cytiva will lay off 85 employees from its facility in Westborough, Massachusetts, beginning at the end of the week, according to a Worker Adjustment and Retraining Notification alert filed with the state. |
By Nick Paul Taylor ZoomRx has dug into its data to see what messages resonate with healthcare professionals at different stages in pharma launches, generating a roadmap of which themes drugmakers should push and when. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," we hear from Steven McCarroll, Ph.D., whose research team at the Broad Institute of MIT and Harvard recently uncovered new insights into the cause of Huntington's disease. |
|
|---|
|
|
|
Wednesday, April 9, 2025 | 10am ET / 7am PTLearn the key steps for successfully entering Japan’s pharmaceutical market. This webinar covers regulatory requirements, compliance strategies, supply chain best practices, and common challenges. Gain expert insights to navigate this high-potential market with confidence. Don’t miss out—register now to secure your spot! 
|
|
Whitepaper Read about four trends that will shape the innovations, therapies, & market landscape in oncology during 2025 & beyond. Presented by Blue Matter, strategic consultants in the life sciences |
Whitepaper Discover how to revolutionize your vaccine trials with Avacare's latest white paper. Gain exclusive access to innovative, data-driven recruitment strategies that ensure diverse, efficient, and high-quality vaccine trials. Sponsored by: Avacare Clinical Research Network |
Whitepaper Develop your CAR molecule faster Sponsored by: Cell Signaling Technology |
| Submissions Open Early August |
|
|
| |
|
+(1).png)
